Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Creative Commons License

Panaccione R., Colombel J., Travis S. P. L., Bossuyt P., Baert F., Vanasek T., ...More

GUT, vol.69, no.4, pp.658-664, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 69 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.1136/gutjnl-2019-318256
  • Journal Name: GUT
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.658-664
  • Bezmialem Vakıf University Affiliated: Yes


Objective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn's disease (CD) naive to immunosuppressants and biologics using a UK public payer perspective.